Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study‐3 and Circulating Cell‐Free Genome Atlas Substudy 3

Key Points

• This research aims to estimate the duration of detectable circulating tumor DNA (ctDNA) in various cancers to inform early detection methods.
• Analyzed data from 3669 cancer patients in two studies.
• Estimated ctDNA detectable duration across multiple cancer types and stages.
• Used computational models to evaluate prognostic implications.
• Average ctDNA shedding duration varies by cancer type and stage.
• Results suggest optimal time frames for future screening studies.
• Findings indicate that understanding ctDNA dynamics can enhance early detection strategies.